Nasdaq · Biological Products, (No Diagnostic Substances)
American multinational biopharmaceutical company
41 entities across 15 jurisdictions, 3 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-13 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Amgen (Europe) GmbH | Switzerland | |
| Amgen Canada Inc. | Canada | |
| Amgen Fremont Inc. | Delaware | |
| Amgen Global Finance B.V. | Netherlands | |
| Amgen Global Technology Unlimited Company | Ireland | |
| Amgen GmbH Germany | Germany | |
| Amgen International Holdings Inc. | Delaware | |
| Amgen K.K. | Japan | |
| Amgen K-A, Inc. | Delaware | |
| Amgen Manufacturing Limited LLC | Puerto Rico | |
| Amgen Rare Disease Holdings Inc. | Delaware | |
| Amgen Research (Munich) GmbH | Germany | |
| Amgen S.A.S. | France | |
| Amgen S.p.A. | Italy | |
| Amgen SF, LLC | Delaware | |
| Amgen Singapore Holding Pte. Ltd. | Singapore | |
| Amgen Singapore Manufacturing Pte. Ltd. | Singapore | |
| Amgen Technology (Ireland) Unlimited Company | Ireland | |
| Amgen Technology, Limited | Bermuda | offshore centre |
| Amgen USA Inc. | Delaware | |
| Amgen Worldwide Holdings B.V. | Netherlands | |
| Amgen, S.A. | Spain | |
| BioVex LLC | Delaware | |
| ChemoCentryx, Inc. | Delaware | |
| Five Prime Therapeutics, Inc. | Delaware | |
| Horizon Therapeutics Finance S.à.r.l | Luxembourg | offshore centre |
| Horizon Therapeutics Holdings Limited | Ireland | |
| Horizon Therapeutics Ireland DAC | Ireland | |
| Horizon Therapeutics Limited | Ireland | |
| Horizon Therapeutics Services LLC | Delaware | |
| Horizon Therapeutics U.S. Holding LLC | Delaware | |
| Horizon Therapeutics USA, Inc. | Delaware | |
| HZNP Finance Limited | Bermuda | offshore centre |
| Immunex Corporation | Washington | |
| Immunex Rhode Island Corporation | Delaware | |
| Onyx Pharmaceuticals, Inc. | Delaware | |
| Onyx Therapeutics, Inc. | Delaware | |
| Pillartree Limited | Ireland | |
| Saga Investments Coöperatief U.A. | Netherlands | |
| TeneoBio, Inc. | Delaware | |
| Viela Bio, Inc. | Delaware |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $25.4B | $7.3B | $9.9B | — | 590,000,000 |
| FY2021 | $26.0B | $5.9B | $8.4B | — | 573,000,000 |
| FY2022 | $26.3B | $6.6B | $8.8B | — | 541,000,000 |
| FY2023 | $28.2B | $6.7B | $7.4B | — | 538,000,000 |
| FY2024 | $33.4B | $4.1B | $10.4B | — | 541,000,000 |
| FY2025 | $36.8B | $7.7B | $8.1B | — | 542,000,000 |
15 institutions tracked — 8 added, 6 reduced, 1 opened a new position. Index money added 2,539,137 shares while active managers cut 545,581.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | Active fund | 3,971,184 | −3,466,753 | $1.4B |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 2,742,271 | +2,514,254 | $993.0M |
| BlackRock, Inc. | Index | 49,362,016 | +2,261,544 | $17.9B |
| MORGAN STANLEY | Active fund | 13,653,692 | −2,182,366 | $4.9B |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 3,956,992 | +2,089,803 | $1.4B |
| CITADEL ADVISORS LLC | Hedge fund | 2,469,384 | +925,421 | $894.2M |
| FMR LLC | Active fund | 3,491,822 | −284,608 | $1.3B |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 15,696,068 | +265,544 | $5.7B |
| Capital World Investors | Active fund | 29,075,329 | −213,014 | $10.5B |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 300,007 | +147,785 | $107.8M |
| BANK OF AMERICA CORP /DE/ | Active fund | 5,058,830 | −62,198 | $1.8B |
| Point72 Asset Management, L.P. | Hedge fund | 26,400 | −21,000 | $9.6M |
| STATE STREET CORP | Index | 30,560,537 | +12,049 | $11.1B |
| Bridgewater Associates, LP | Hedge fund | 21,869 | +7,095 | $7.9M |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
AMGEN INC files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
